

INTRODUCTION .....	XI
STUDY GOALS AND OBJECTIVES.....	XI
REASONS FOR DOING THIS STUDY .....	XI
SCOPE OF REPORT .....	XI
INTENDED AUDIENCE.....	XI
METHODOLOGY .....	XII
INFORMATION SOURCES.....	XII
ABOUT THE AUTHOR.....	XII
RELATED BCC WORK CREDENTIALS .....	XII
BCC ONLINE SERVICES.....	XIII
DISCLAIMER .....	XIII
 EXECUTIVE SUMMARY .....	 XIV
<i>SUMMARY TABLE WORLDWIDE SALES OF MONOCLONAL     THERAPEUTIC AND COMPANION DIAGNOSTICS, THROUGH     2012 (\$ BILLIONS)</i> .....	   XV
<i>SUMMARY FIGURE WORLDWIDE SALES OF MONOCLONAL     THERAPEUTIC AND COMPANION DIAGNOSTICS, 2005-2012     (\$ BILLIONS)</i> .....	   XV
MAB GROWTH IN THERAPEUTICS .....	XV
PHARMA MOVES IN .....	XVI
MAB GROWTH IN DIAGNOSTICS .....	XVI
KEY DRIVERS AND CHALLENGES.....	XVII
SIGNIFICANT TRENDS .....	XVIII
 OVERVIEW .....	 1
<i>TABLE 1 BIOPHARMACEUTICAL CATEGORIES</i> .....	 1
<i>TABLE 2 MONOCLONAL ANTIBODIES APPROVED FOR DISEASE     THERAPY*</i> .....	  2
<i>TABLE 2 (CONTINUED)</i> .....	3
<i>FIGURE 1 COMPOSITION OF COMMERCIALIZED ANTIBODIES BY     TYPE, 2007 AND 2012 (%)</i> .....	  4
OVERVIEWC(CONTINUED) .....	5
<i>FIGURE 2 ANTIBODY ILLUSTRATED</i> .....	6
MAB TECHNOLOGY: BEGINNINGS AND MOVEMENTS.....	6
<i>TABLE 3 TIMELINE FOR MAB DEVELOPMENT</i> .....	7
MOVING TOWARDS HUMANIZATION .....	7
ANTIBODY TECHNOLOGY TYPES.....	8
HUMANIZATION .....	8
<i>TABLE 4 WORLDWIDE FORECAST OF THERAPEUTIC     MONOCLONAL ANTIBODIES, BY TYPE, THROUGH 2012     (\$ BILLIONS)</i> .....	   9
SUPERHUMANIZATION .....	9
SMART TECHNOLOGY.....	10

<i>TABLE 5 SMART TECHNOLOGY ROYALTIES BY LICENSEE AND PRODUCT AS A PERCENTAGE OF TOTAL ROYALTY REVENUE: EXAMPLE OF TECHNOLOGY ROYALTY POTENTIAL (%)</i> .....	11
FULLY HUMAN TECHNOLOGY .....	11
PHAGE DISPLAY .....	11
Phage Display (Continued) .....	12
CRUCCELL'S PER.C6 AND MABSTRACT .....	13
TRANSGENIC MICE .....	14
<i>TABLE 6 TRANSGENIC TECHNOLOGIES</i> .....	15
<i>TABLE 6 (CONTINUED)</i> .....	16
EMERGING ANTIBODY TECHNOLOGY TYPES .....	17
Fragments .....	17
Single Chain Antibodies .....	17
Bispecific Antibodies .....	18
Conjugation .....	19
<i>TABLE 7 LEADING CONJUGATION TECHNOLOGIES</i> .....	20
TECHNOLOGY RELATED ISSUES AND CHALLENGES .....	21
Optimization .....	21
Adjusting Glycosylation .....	21
<i>TABLE 8 ANTIBODY TECHNOLOGY BEHIND COMMERCIALIZED MABS</i> .....	22
MANUFACTURING .....	23
LEGALITY AND INTELLECTUAL PROPERTY .....	24
Legality and Intellectual Property (Continued) .....	25
<i>TABLE 9 CAT'S PHAGE AND RIBOSOME DISPLAY PATENTS</i> .....	26
PHARMACEUTICAL AND BIOTECHNOLOGY LANDSCAPE .....	26
<i>TABLE 10 PHARMA'S MAB-RELATED ACQUISITIONS</i> .....	27
<i>FIGURE 3 THE SYNERGY OF PHARMA AND BIOTECH</i> .....	28
<i>TABLE 11 GLOBAL SNAPSHOT: BIOTECHNOLOGY INDUSTRY*</i> .....	28
Pharmaceutical and Biotechnology ... (Continued) .....	29
MABS IN THERAPEUTICS .....	30
<i>FIGURE 4 SHARE OF MONOCLONAL ANTIBODY THERAPY MARKET BY THERAPEUTIC AREA, 2007 AND 2012 (%)</i> .....	30
<i>FIGURE 4 (CONTINUED)</i> .....	31
SIGNIFICANT TRENDS .....	31
EXPANDING INDICATIONS .....	31
NOVEL MECHANISMS OF ACTION .....	32
NOVEL APPLICATIONS .....	33
GROUPS OR COMBINATIONS OF ANTIBODIES AND OTHER AGENTS .....	33
FRAGMENTS OF ANTIBODIES (FABS) .....	33
COMPANION DIAGNOSTICS .....	34
MARKETS FOR THERAPEUTIC MABS COMPARED .....	34

<i>TABLE 12 MARKET VALUE OF BIOPHARMACEUTICAL THERAPEUTIC AREAS, THROUGH 2012 (\$ BILLIONS)</i> .....	35
<i>TABLE 13 WORLDWIDE SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, BY THERAPEUTIC AREA, THROUGH 2012 (\$ BILLIONS)</i> .....	36
<i>TABLE 14 GROWTH OF COMMERCIALIZED MONOCLONAL ANTIBODIES BY THERAPEUTIC AREA, THROUGH 2012 (NUMBER OF COMMERCIALIZED ANTIBODIES EACH YEAR)</i> .....	36
<i>TABLE 15 BIOPHARMACEUTICAL MARKET VALUE OF VARIOUS DISEASES/CONDITIONS, THROUGH 2012 (\$ BILLIONS)</i> .....	37
THERAPEUTIC AREAS DETAILED .....	37
ONCOLOGY .....	37
Oncology (Continued) .....	38
ONCOLOGY MARKET AS A WHOLE .....	39
<i>TABLE 16 CANCER'S GLOBAL ANNUAL DEATH TOLL</i> .....	40
<i>TABLE 17 ESTIMATED NEW CASES OF CANCER IN THE U.S., 2007</i> .....	40
AIIID .....	40
RESPIRATORY .....	41
TRANSPLANTATION .....	41
CENTRAL NERVOUS SYSTEM (CNS).....	42
<i>TABLE 18 CNS GLOBAL MARKET VALUES (\$ BILLIONS)</i> .....	42
CARDIOVASCULAR (CV) .....	42
INFECTIOUS DISEASE.....	43
OPHTHALMOLOGY.....	44
BLOOD DISORDERS .....	44
WOMEN'S HEALTH/OSTEOPOROSIS .....	45
FREQUENT MAB THERAPEUTIC TARGETS.....	45
<i>TABLE 19 COMMON ANTIGEN TARGETS EXPLAINED</i> .....	45
<i>TABLE 19 (CONTINUED)</i> .....	46
<i>FIGURE 5 MAJOR MAB ANTIGEN TARGETS COMMERCIALIZED</i> .....	47
THERAPEUTIC MABS IN THE PIPELINE.....	47
<i>TABLE 20 THERAPEUTIC PIPELINE: SELECTED MABS IN DEVELOPMENT</i> .....	48
<i>TABLE 20 (CONTINUED)</i> .....	49
<i>TABLE 20 (CONTINUED)</i> .....	50
<i>TABLE 20 (CONTINUED)</i> .....	51
<i>TABLE 20 (CONTINUED)</i> .....	52
<i>TABLE 20 (CONTINUED)</i> .....	53
<i>TABLE 20 (CONTINUED)</i> .....	54
<i>TABLE 20 (CONTINUED)</i> .....	55
<i>TABLE 20 (CONTINUED)</i> .....	56
MABS IN DIAGNOSTICS.....	57
MABS IN DIAGNOSTICS .....	57

<i>TABLE 21 WORLDWIDE VALUE OF MAB-ASSOCIATED DIAGNOSTICS, BY TECHNOLOGY TYPE, THROUGH 2012 (\$ BILLIONS)</i> .....	58
KEY DRIVERS .....	58
MABS IN DIAGNOSTIC RADIOPHARMACEUTICALS.....	58
MAbs in Diagnostic Radiopharmaceuticals (Continued) .....	59
<i>TABLE 22 SCANNING TECHNOLOGIES THAT ARE USED WITH DIAGNOSTIC RADIOPHARMACEUTICALS</i> .....	60
CHALLENGES FOR MAB DIAGNOSTIC RADIOPHARMACEUTICALS.....	60
MARKET STATUS.....	61
<i>TABLE 23 MAB-BASED DIAGNOSTIC RADIOPHARMACEUTICALS: CURRENT AND EMERGING</i> .....	62
FUTURE GROWTH EXPECTED.....	63
PATHWAYS FORWARD .....	64
MABS IN IMMUNOASSAYS .....	65
<i>FIGURE 6 WORLDWIDE IN-VITRO DIAGNOSTIC MARKET SHARE BY THERAPEUTIC AREA, 2006 (%)</i> .....	66
IHC AND COMPANION DIAGNOSTICS .....	67
COMPANY MOVEMENTS.....	67
Company Movements (Continued).....	68
REGULATORY PATHMAKING .....	69
EMERGING COMPANION DIAGNOSTIC PRESENCE.....	69
A NEW PARADIGM: MULTIFUNCTIONAL MABS IN DEVELOPMENT.....	70
<i>TABLE 24 A NEW PARADIGM: MULTIFUNCTIONAL MAB DEVELOPMENT PIPELINE</i> .....	70
<i>TABLE 24 (CONTINUED)</i> .....	71
COMPANY PROFILES .....	72
ABGENIX, INC. (NOW AMGEN) .....	72
ABBOTT LABORATORIES.....	73
<i>TABLE 25 ABBOTT PRODUCT CATEGORIES</i> .....	74
<i>TABLE 26 HUMIRA'S LIFECYCLE TO DATE</i> .....	74
AERES BIOMEDICAL, LTD.....	75
ALEXION PHARMACEUTICALS, INC. ....	75
ALEXION PHARMACEUTICALS, INC. (CONTINUED).....	76
AMGEN, INC. ....	77
<i>TABLE 27 AMGEN'S PRODUCTS IN PHASE II OR LATER DEVELOPMENT</i> .....	78
ARIUS RESEARCH, INC.....	79
ASTRAZENECA.....	79
<i>TABLE 28 ASTRAZENECA'S KEY BIOLOGICALS IN CLINICAL TRIALS</i> .....	80
<i>TABLE 29 ASTRAZENECA'S KEY BIOLOGICALS IN PRECLINICALS</i> .....	81

BECKMAN COULTER.....	81
BIOGEN IDEC, INC.....	82
BIOGEN IDEC, INC. (CONTINUED).....	83
BIOGEN IDEC, INC. (CONTINUED).....	84
CAMBRIDGE ANTIBODY TECHNOLOGY, LTD.....	85
CENTOCOR.....	86
CHUGAI PHARMACEUTICAL.....	87
<i>TABLE 30 CHUGAI'S ANTIBODY-BASED PIPELINE.....</i>	<i>88</i>
<i>TABLE 30 (CONTINUED).....</i>	<i>89</i>
CRUCCELL.....	89
CURAGEN CORPORATION.....	90
<i>TABLE 31 CURAGEN'S ANTIBODY-BASED DRUG CANDIDATES.....</i>	<i>91</i>
<i>TABLE 31 (CONTINUED).....</i>	<i>92</i>
CYTOGEN CORPORATION.....	92
DYAX CORPORATION.....	93
ELAN CORPORATION.....	94
ELAN CORPORATION (CONTINUED).....	95
EISAI CO., LTD.....	96
<i>TABLE 32 EISAI'S (MORPHOTECK ACQUISITION) MONOCLONAL PIPELINE.....</i>	<i>97</i>
GENENTECH, INC.....	98
GENENTECH, INC. (CONTINUED).....	99
<i>TABLE 33 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES.....</i>	<i>100</i>
<i>TABLE 34 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES.....</i>	<i>101</i>
GENMAB A/S.....	101
GENZYME CORPORATION.....	102
GLAXOSMITHKLINE, PLC.....	103
GLAXOSMITHKLINE, PLC (CONTINUED).....	104
IMCLONE SYSTEMS.....	105
IMMUNOGEN.....	105
IMMUNOMEDICS, INC.....	106
<i>TABLE 35 IMMUNOMEDICS' THERAPEUTIC PRODUCT PIPELINE.....</i>	<i>107</i>
LONZA BIOLOGICS.....	108
MEDAREX, INC.....	109
<i>TABLE 36 MEDAREX'S PRODUCT PIPELINE.....</i>	<i>110</i>
MERCK SERONO.....	111
MICROMET.....	112
<i>TABLE 37 MICROMET'S PIPELINE.....</i>	<i>113</i>
MILLENNIUM PHARMACEUTICALS, INC.....	114
<i>TABLE 38 MILLENNIUM'S PRODUCTS IN PHASE II OR LATER DEVELOPMENT.....</i>	<i>115</i>
MORPHOSYS AG.....	115

<i>TABLE 39 MORPHOSYS HUCAL-BASED ANTIBODY PRODUCTS</i> .....	116
<i>TABLE 40 MORPHOSYS' PATENT PORTFOLIO</i> .....	117
NABI PHARMACEUTICALS.....	117
NOVARTIS PHARMACEUTICALS CORPORATION .....	118
ORTHO BIOTECH PRODUCTS .....	119
ONYVAX .....	120
PDL BIOPHARMA.....	121
<i>TABLE 41 PDL BIOPHARMA'S PRODUCTS IN PHASE II OR LATER</i> .....	122
PROGENICS PHARMACEUTICALS .....	123
REGENERON PHARMACEUTICALS, INC. ....	123
ROCHE .....	124
SEATTLE GENETICS.....	125
TANABE SEIYAKU CO., LTD.....	126
<i>TABLE 42 TANABE SEIYAKU'S ANTIBODY-BASED PIPELINE</i> .....	127
UCB S.A. ....	128
VIVALIS .....	130
VIVENTIA BIOTECH, INC.....	131
WYETH PHARMACEUTICALS, INC. ....	131
XOMA, LTD.....	132